United States - English - NLM (National Library of Medicine)

myokardia, inc. - mavacamten (unii: qx45b99r3j) (mavacamten - unii:qx45b99r3j) - camzyos® is indicated for the treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms. camzyos is contraindicated with concomitant use of: risk summary based on animal data, camzyos may cause fetal harm when administered to a pregnant female. there are no human data on the use of camzyos during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. the underlying maternal condition during pregnancy poses a risk to the mother and fetus (see clinical considerations) . advise pregnant females about the potential risk to the fetus with maternal exposure to camzyos during pregnancy. in animal embryo-fetal development studies, mavacamten-related decreases in mean fetal body weight, reductions in fetal ossification of bones, and increases in post-implantation loss (early and/or late resorptions) were observed in rats and inc

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 5 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide yellow; mannitol; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 2.5 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide black; mannitol; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 15 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide black; mannitol; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mavacamten, quantity: 10 mg - capsule, hard - excipient ingredients: magnesium stearate; hypromellose; croscarmellose sodium; gelatin; silicon dioxide; iron oxide red; mannitol; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - camzyos is indicated for the treatment of adults with symptomatic nyha class ii-iii obstructive hypertrophic cardiomyopathy.

United States - English - NLM (National Library of Medicine)

wizyoung co., ltd - betaine (3%), scutellaria baicalensis root extract (0.01%) - skin protectant moisturizes and helps skin look visibly firm, elastic and radiant. keep skin smooth and soft. brightening and wrinkle care.

United States - English - NLM (National Library of Medicine)

wizyoung co., ltd - betaine (3%), scutellaria baicalensis root extract (0.01%) - skin protectant moisturizes and helps skin look visibly firm, elastic and radiant. keep skin smooth and soft. brightening and wrinkle care.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - other cardiac preparations - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

United States - English - NLM (National Library of Medicine)

shenzhen deyintang biotechnology co., ltd. - collagen, soluble, fish skin (unii: 8jc99xgu4w) (collagen, soluble, fish skin - unii:8jc99xgu4w), momordica charantia fruit (unii: ua63y8u89u) (momordica charantia fruit - unii:ua63y8u89u), lycium barbarum fruit (unii: 930626mwdl) (lycium barbarum fruit - unii:930626mwdl), calendula officinalis flowering top (unii: 18e7415pxq) (calendula officinalis flowering top - unii:18e7415pxq), salvia microphylla whole (unii: qe59m93omq) (salvia microphylla whole - unii:qe59m93omq) - health care please eat according to the recommended amount,it is not beneficial to eat too much.

Canada - English - Health Canada

bristol-myers squibb canada - mavacamten - capsule - 2.5mg - mavacamten 2.5mg